Clinical Trial Update: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating AST-301 (pNGVL3-hICD), a therapeutic cancer vaccine, for gastric cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• AST-301 (pNGVL3-hICD)

Snippet

Sponsor: Aston Sci. Inc. | Conditions: Gastric Cancer | Phase 2 | Status: RECRUITING